RU2001124816A - Quinazoline derivatives as angiogenesis inhibitors - Google Patents

Claims (30)

1. The use of the compounds of formula I

where ring C represents an 8-, 9-, 10-, 12- or 13-membered bicyclic or tricyclic moiety, which may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may contain 1-3 heteroatoms independently selected from O, N and S; Z represents —O—, —NH—, —S—, —CH ₂ - or a single bond; n is 0 to 5; m is 0 to 3; R ² represents hydrogen, hydroxy, halogen, cyano, nitro, trifluoromethyl, C _1-3 alkyl, C _1-3 alkoxy, C _1-3 alkylsulfanyl, -NR ³ R ⁴ , where R ³ and R ⁴ , which may be the same or different, each represents hydrogen or C _1-3 alkyl, or R ⁵ X ¹ , where X ¹ represents a single bond, —O—, —CH ₂ -, —OC (O) -, —C (O) -, - S-, -SO-, -SO ₂ -, -NR ⁶ C (O), -C (O) NR ⁷ , -SO ₂ NR ⁸ -, -NR ⁹ SO ₂ - or-NR ¹⁰ -, where R ⁶ , R ⁷ , R ⁸ , R ⁹ and R ¹⁰ each independently represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ^{5 is} selected from one of the following twenty two groups: 1) hydrogen, oxiranyl C _1-4 alkyl or C _1-5 alkyl, which may be unsubstituted or which may be substituted by one or more groups selected from hydroxy, fluorine, chlorine, bromine and amino; 2) C _1-5 alkylX ² C (O) R ¹¹ where X ² is —O— or —NR ¹² -, where R ¹² is hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ¹¹ represents C _1-3 alkyl, —NR ¹³ R ¹⁴ or —OR ¹⁵ , where R ¹³ , R ¹⁴ and R ¹⁵ , which may be the same or different, each represents hydrogen, C _1-5 alkyl or C _1-3 alkoxyC _2-3 alkyl; 3) C _1-5 alkylX ³ R ¹⁶ , where X ³ is —O—, —S—, —SO—, —SO ₂ -, —OC (O) -, —NR ¹⁷ C (O) -, —C (O) NR ¹⁸ -, -SO ₂ NR ¹⁹ -, -NR ²⁰ SO ₂ - or -NR ²¹ -, where R ¹⁷ , R ¹⁸ , R ¹⁹ , R ²⁰ and R ²¹ each independently represents hydrogen, C _{1 -3} alkyl or C _1-3 alkoxyC _2-3 alkyl, R ¹⁶ represents hydrogen, C _1-3 alkyl, cyclopentyl, cyclohexyl or a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms independently selected from O, S and N , said C _1-3 vlkilnaya group may contain 1 or 2 substituents selected from oxo, hydroxy, halogeno and C _1-4 alkoxy, and said cyclic group may contain 1 or 2 substituents Selected from oxo, hydroxy, halogen, cyano, C _1-4 cyanoalkyl, C _1-4 alkyl, C _1-4 hydroxyalkyl, C _1-4 alkoxy, C _1-4 alkoksiS _1-4 alkyl, C _1-4 alkilsulfonilS _1-4 alkyl, C _1-4 alkoxycarbonyl, C _1-4 aminoalkyl, C _1-4 alkylamino, di (C _1-4 alkyl) amino, C _1-4 alkylamino C _1-4 alkyl, di (C _1-4 alkyl ) aminoC _1-4 alkyl, C _1-4 alkilaminoS _1-4 alkoxy, di (C _1-4 alkyl) aminoC _1-4 alkoxy and a group - (- O-) _f (C _1-4 alkyl) _g koltsoD (wherein f = 0 or 1, g = 0 or 1, ring D represents a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms independently selected from O, S and N, said cyclic a group may contain one or more substituents selected from C _1-4 alkyl; 4) C _1-5 alkylX ⁴ C _1-5 alkylX ⁵ R ²² , where X ⁴ and X ⁵ , which may be the same or different, are each, —O—, —S—, —SO—, —SO ₂ -, -NR ²³ C (O) -, -C (O) NR ²⁴ -, -SO ₂ NR ²⁵ -, -NR ²⁶ SO ₂ -or -NR ²⁷ -, where R ²³ , R ²⁴ , R ²⁵ , R ²⁶ and R ²⁷ each independently represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ²² represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl; 5) R ²⁸ , where R ²⁸ represents a 5-6 membered saturated heterocyclic group (bonded via carbon or nitrogen) with 1-2 heteroatoms selected independently from O, S and N, said heterocyclic group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-4 cyanoalkyl, C _1-4 alkyl, C _1-4 hydroxyalkyl, C _1-4 alkoxy, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylsulfonyl C _{1- 4} alkyl, C _1-4 alkoxycarbonyl, C _1-4 aminoalkyl, C _1-4 alkylamino, di (C _1-4 alkyl) amino, C _1-4 alkylamino C _1-4 alkyl, di (C _1-4 alkyl) aminoC _1-4 alkyl, C _1-4 alkylamino C _1-4 alkoxy, di (C _1-4 alkyl) amino C _1-4 alkoxy and groups - (- O-) _f (C _1-4 alkyl) _g ring D, where f = 0 or 1, g = 0 or 1, ring D represents 5- A 6-membered saturated heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, said cyclic group may contain one or more substituents selected from C _1-4 alkyl; 6) C _1-5 alkyl R ²⁸ , where R ²⁸ is as defined herein; 7) C _2-5 alkenyl R ²⁸ , where R ²⁸ is as defined herein; 8) C _2-5 alkynyl R ²⁸ , where R ²⁸ is as defined herein; 9) R ²⁹ , where R ²⁹ represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, S and N, said pyridonic, phenyl or an aromatic heterocyclic group may contain up to 5 substituents selected from hydroxy, halogen, amino, C _1-4 alkyl, C _1-4 alkoxy, C _1-4 hydroxyalkyl, C _1-4 aminoalkyl, C _1-4 alkylamino, C _{1- 4} hydroxyalkoxy, carboxy, trifluoromethyl, cyano, —C (O) NR ³⁰ R ³¹ , —NR ³² C (O) R ³³ -, where R ³⁰ , R ³¹ , R ³² and R ³³ , which may be the same or different which may be the same or different, each independently represents hydrogen, C _1-4 alkyl or C _1-3 alkoxyC _2-3 alkyl, and the groups - (- O-) _f (C _1-4 alkyl) _g ring D, where f = 0 or 1, g = 0 or 1, ring D represents a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, said cyclic group may contain one or more substituents selected from C _1-4 alkyl; 10) C _1-5 alkylR ²⁹ wherein R ²⁹ is as defined herein; 11) C _2-5 alkenyl R ²⁹ , where R ²⁹ is as defined herein; 12) C _2-5 alkynyl R ²⁹ , where R ²⁹ is as defined herein; 13) C _1-5 alkylX ⁵ R ²⁹ , where X ⁶ is —O—, —S—, —SO—, —SO ₂ -, —NR ³⁴ C (O) -, —C (O) NR ³⁵ -, -SO ₂ NR ³⁶ -, -NR ³⁷ SO ₂ - or -NR ³⁸ - (where R ³⁴ , R ³⁵ , R ³⁶ , R ³⁷ and R ³⁸ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ²⁹ is as previously defined; 14) C _2-5 alkenylX ⁷ R ²⁹ , where X ⁷ represents —O—, —S—, —SO—, —SO ₂ -, —NR ³⁹ C (O) -, —C (O) NR ⁴⁰ -, -SO ₂ NR ⁴¹ -, -NR ⁴² SO ₂ - or -NR ⁴³ -, where R ³⁹ , R ⁴⁰ , R ⁴¹ , R ⁴² and R ⁴³ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ²⁹ is as defined herein; 15) C _2-5 alkynyl X ⁸ R ²⁹ , where X ⁸ represents —O—, —S—, —SO—, —SO ₂ -, —NR ⁴⁴ C (O) -, —C (O) NR ⁴⁵ -, -SO ₂ NR ⁴⁶ -, -NR ⁴⁷ SO ₂ - or -NR ⁴⁸ - (where R ⁴⁴ , R ⁴⁵ , R ⁴⁶ , R ⁴⁷ and R ⁴⁸ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ²⁹ is as defined herein; 16) C _1-4 alkylX ⁹ C _1-4 alkylR ²⁹ , where X ⁹ is —O—, —S—, —SO—, —SO ₂ -, —NR ⁴⁹ C (O) -, —C (O) NR ⁵⁰ -, -SO ₂ NR ⁵¹ -, -NR ⁵² SO ₂ - or -NR ⁵³ -, where R ⁴⁹ , R ⁵⁰ , R ⁵¹ , R ⁵² and R ⁵³ each independently represent hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ²⁹ is as defined herein; 17) C _1-4 alkylX ⁹ C _1-4 alkylR ²⁸ , where X ⁹ and R ²⁸ are as defined herein; 18) C _2-5 alkenyl, which may be unsubstituted or may be substituted by one or more groups selected from hydroxy, fluoro, amino, C _1-4 alkylamino, N, N-di (C _1-4 alkyl) amino, aminosulfonyl N-C _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 19) C _2-5 alkynyl, which may be unsubstituted or may be substituted by one or more groups selected from hydroxy, fluoro, amino, C _1-4 alkylamino, N, N-di (C _1-4 alkyl) amino, aminosulfonyl N-C _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 20) C _2-5 alkenyl X ⁹ C _1-4 alkyl R ²⁸ , where X ⁹ and R ²⁸ are as defined herein; 21) C _2-4 alkynylX ⁹ C _1-4 alkyl R ²⁸ , where X ⁹ and R ²⁸ are as defined herein; and 22) C _1-4 alkylR ⁵⁴ (C _1-4 alkyl) _q (X ⁹⁾ _{r R} ^55, wherein X ⁹ is as defined herein, q = 0 or 1, r = 0 or 1, and R ⁵⁴ and R ⁵⁵ are each independently selected from hydrogen, C _1-3 alkyl, cyclopentyl, cyclohexyl and a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, indicated C _{1- The 3} alkyl group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen and C _1-4 alkoxy, and the specified cyclic group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-4 cyanoalkyl , _1-4 alkyl, C _1-4 hydroxyalkyl, C _1-4 alkoxy, C _1-4 alkoksiS _1-4 alkyl, C _1-4 alkilsulfonilS _1-4 alkyl, C _1-4 alkoxycarbonyl, C _1-4 aminoalkyl, C _1-4 alkylamino, di (C _1-4 alkyl) amino, C _1-4 alkilaminoS _1-4 alkyl, di (C _1-4 alkyl) aminoC _1-4 alkyl, C _1-4 alkilaminoS _1-4 alkoxy, di (C _1-4 alkyl) amino C _1-4 alkoxy and the groups - (- O-) _f (C _1-4 alkyl) _g ring D, where f = 0 or 1, g = 0 or 1, and ring D represents 5- A 6-membered saturated heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, said cyclic group may contain one or more substituents, selected from C _1-4 alkyl, provided that R ⁵⁴ cannot represent hydrogen), and additionally, where any C _1-5 alkyl, C _2-5 alkenyl or C _2-5 alkynyl group in R ⁵ X ¹ may contain one or more substituents selected from hydroxy, halogen and amino; R ¹ represents hydrogen, oxo, halogen, hydroxy, C _1-4 alkoxy, C _1-4 alkyl, C _1-4 alkoxymethyl, C _1-4 alkanoyl, C _1-4 haloalkyl, cyano, amino, C _2-5 alkenyl , C _2-5 alkynyl, C _1-3 alkanoyloxy, nitro, C _1-4 alkanoylamino, C _1-4 alkoxycarbonyl, C _1-4 alkylsulfanyl, C _1-4 alkylsulfinyl, C _1-4 alkylsulfonyl, carbamoyl, N-C _1-4 alkylcarbamoyl, N, N-di (C _1-4 alkyl) carbamoyl, aminosulfonyl, N-C _1-4 alkylaminosulfonyl, N, N-di (C _1-4 alkyl) aminosulfonyl, N- (C _1-4 alkylsulfonyl) amino, N- (C _1-4 alkylsulfonyl) -N- (C _1-4 alkyl) amino, N, N-di (C _1-4 alkylsulfonyl) amino, C _3-7 alkylene chain linked with two ring C carbon atoms, C _1-4 alkanoilaminoS _1-4 alkyl, carboxy or a group R ⁵⁶ X ^10, where X ¹⁰ represents a single bond, -O-, -CH ₂ -, -OC (O) -, -C ( O) -, -S-, -SO-, -SO ₂ -, -NR ⁵⁷ C (O), -C (O) NR ⁵⁸ , -SO ₂ NR ⁵⁹ -, -NR ⁶⁰ SO ₂ - or -NR ⁶¹ - where R ⁵⁷ , R ⁵⁸ , R ⁵⁹ , R ⁶⁰ and R ⁶¹ each independently represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ^{56 is} selected from one of the following twenty two groups : 1) hydrogen, oxiranyl C _1-4 alkyl or C _1-5 alkyl, which may be unsubstituted or which may be substituted by one or more groups selected from hydroxy, fluorine, chlorine, bromine and amino; 2) C _1-5 alkylX ¹¹ (O) R ⁶² , where X ¹¹ is —O— or —NR ⁶³ -, where R ⁶³ is hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, and R ⁶² represents C _1-3 alkyl, —NR ⁶⁴ R ⁶⁵ or —OR ⁶⁶ , where R ⁶⁴ , R ⁶⁵ and R ⁶⁶ , which may be the same or different, each represents hydrogen, C _1-5 alkyl or C _1-3 alkoxyC _2-3 alkyl; 3) C _1-5 alkylX ¹² R ⁶⁷ , where X ¹² is —O—, —S—, —SO—, —SO ₂ -, —OC (O) -, —NR ⁶⁸ (O) -, —C ( O) NR ⁶⁹ -, -SO ₂ NR ⁷⁰ -, -NR ⁷¹ SO ₂ - or -NR ⁷² -, where R ⁶⁸ , R ⁶⁹ , R ⁷⁰ , R ⁷¹ and R ⁷² , each independently represents hydrogen, C _{1 -3} alkyl or C _1-3 alkoxyC _2-3 alkyl, R ⁶⁷ represents hydrogen, C _1-3 alkyl, cyclopentyl, cyclohexyl or a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms independently selected from O, S and N , said C _1-3 alkyl group may contain 1 or 2 substituents selected from oxo, hydroxy, halogeno and C _1-4 alkoxy, and said cyclic group may contain 1 or 2 Override I, selected from oxo, hydroxy, halogen, cyano, C _1-4 cyanoalkyl, C _1-4 alkyl, C _1-4 hydroxyalkyl, C _1-4 alkoxy, C _1-4 alkoksiS _1-4 alkyl, C _1-4 alkylsulfonylC _1-4 alkyl, C _1-4 alkoxycarbonyl, C _1-4 aminoalkyl, C _1-4 alkylamino, di (C _1-4 alkyl) amino, C _1-4 alkylamino C _1-4 alkyl, di (C _1-4 alkyl) aminoC _1-4 alkyl, C _1-4 alkilaminoS _1-4 alkoxy, di (C _1-4 alkyl) aminoC _1-4 alkoxy and a group _{- (- O-) f (C} 1-4 alkyl) _g koltsoD, where f = 0 or 1, g = 0 or 1, ring D represents a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms independently selected from O, S and N, said cyclic a group may contain one or more substituents selected from C _1-4 alkyl; 4) C _1-5 alkylX ¹³ C _1-5 alkylX ¹⁴ R ⁷³ , where X ¹³ and X ¹⁴ , which may be the same or different, are each —O—, —S—, —SO—, —SO ₂ -, -NR ⁷⁴ C (O) -, -C (O) NR ⁷⁵ -, -SO ₂ NR ⁷⁶ -, -NR ⁷⁷ SO ₂ - or -NR ⁷⁸ -, where R ⁷⁴ , R ⁷⁵ , R ⁷⁶ , R ⁷⁷ and R ⁷⁸ each independently represent hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ⁷³ represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl; 5) R ⁷⁹ , where R ⁷⁹ represents a 5-6 membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms selected independently from O, S and N, said heterocyclic group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-4 cyanoalkyl, C _1-4 alkyl, C _1-4 hydroxyalkyl, C _1-4 alkoxy, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylsulfonyl C _{1- 4} alkyl, C _1-4 alkoxycarbonyl, C _1-4 aminoalkyl, C _1-4 alkylamino, di (C _1-4 alkyl) amino, C _1-4 alkylamino C _1-4 alkyl, di (C _1-4 alkyl) aminoC _1-4 alkyl, C _1-4 alkylamino C _1-4 alkoxy, di (C _1-4 alkyl) amino C _1-4 alkoxy and the groups - (- O-) _f (C _1-4 alkyl) _g ring D, where f = 0 or 1, g = 0 or 1, and ring D represents, A 5-6 membered saturated heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, said cyclic group may contain one or more substituents selected from C _1-4 alkyl; 6) C _1-5 alkyl R ⁷⁹ , where R ⁷⁹ is as previously defined; 7) C _2-5 alkenyl R ⁷⁹ , where R ⁷⁹ is as previously defined; 8) C _2-5 alkynyl R ⁷⁹ , where R ⁷⁹ is as previously defined; 9) R ⁸⁰ , where R ⁸⁰ represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, S and N, said pyridonic, phenyl or an aromatic heterocyclic group may contain up to 5 substituents selected from hydroxy, halogen, amino, C _1-4 alkyl, C _1-4 alkoxy, C _1-4 hydroxyalkyl, C _1-4 aminoalkyl, C _1-4 alkylamino, C _1-4 hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -C (O) NR ⁸¹ R ^82, -NR ⁸³ C (O) R ⁸⁴ - wherein R ^81, R ^82, R ⁸³ and R ^84, which may be identical if different, each independently represents hydrogen, C _1-4 alkyl or C _1-3 alkoksiS _2-3 alkyl) and a group _{- (- O-) f (C} 1-4 alkyl) _g koltsoD where f = 0 or 1 , g = 0 or 1, and ring D represents a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, said cyclic group may contain one or more substituents selected from C _{1 -4} alkyl; 10) C _1-5 alkyl R ⁸⁰ , where R ⁸⁰ is as previously defined; 11) C _2-5 alkenyl R ⁸⁰ , where R ⁸⁰ is as previously defined; 12) C _2-5 alkynyl R ⁸⁰ , where R ⁸⁰ is as previously defined; 13) C _1-5 alkylX ¹⁵ R ⁸⁰ , where X ¹⁵ represents —O—, —S—, —SO—, —SO ₂ -, —NR ⁸⁵ C (O) -, —C (O) NR ⁸⁶ -, -SO ₂ NR ⁸⁷ -, -NR ⁸⁸ SO ₂ - or -NR ⁸⁹ -, where R ⁸⁵ , R ⁸⁶ , R ⁸⁷ , R ⁸⁸ and R ⁸⁹ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ⁸⁰ is as previously defined; 14) C _2-5 alkenyl X ¹⁶ R ⁸⁰ , where X ¹⁶ represents —O—, —S—, —SO—, —SO ₂ -, —NR ⁹⁰ C (O) -, —C (O) NR ⁹¹ -, -SO ₂ NR ⁹² -, -NR ⁹³ SO ₂ - or -NR ⁹⁴ -, where R ⁹⁰ , R ⁹¹ , R ⁹² , R ⁹³ and R ⁹⁴ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ⁸⁰ is as previously defined; 15) C _2-5 alkynylX ¹⁷ R ⁸⁰ , where X ¹⁷ represents —O—, —S—, —SO—, —SO ₂ -, —NR ⁹⁵ C (O) -, —C (O) NR ⁹⁶ -, -SO ₂ NR ⁹⁷ -, -NR ⁹⁸ SO ₂ - or -NR ⁹⁹ -, where R ⁹⁵ , R ⁹⁶ , R ⁹⁷ , R ⁹⁸ and R ⁹⁹ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ⁸⁰ is as previously defined; 16) C _1-4 alkylX ¹⁸ C _1-4 alkylR ⁸⁰ , where X ¹⁸ is —O—, —S—, —SO—, —SO ₂ -, —NR ¹⁰⁰ C (O) -, —C (O) NR ¹⁰¹ -, -SO ₂ NR ¹⁰² -, -NR ¹⁰³ SO ₂ -or -NR ¹⁰⁴ -, where R ¹⁰⁰ , R ¹⁰¹ , R ¹⁰² , R ¹⁰³ and R ¹⁰⁴ each independently represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, and R ⁸⁰ is as previously defined; 17) C _1-4 alkyl X ¹⁸ C _1-4 alkyl R ⁷⁹ , where X ¹⁸ and R ⁷⁹ are as previously defined; 18) C _2-5 alkenyl, which may be unsubstituted or may be substituted by one or more groups selected from hydroxy, fluoro, amino, C _1-4 alkylamino, N, N-di (C _1-4 alkyl) amino, aminosulfonyl N-C _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 19) C _2-5 alkynyl, which may be unsubstituted or may be substituted by one or more groups selected from hydroxy, fluoro, amino, C _1-4 alkylamino, N, N-di (C _1-4 alkyl) amino, aminosulfonyl N-C _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 20) C _2-5 alkenyl X ¹⁸ C _1-4 alkyl R ⁷⁹ , wherein X ¹⁸ and R ⁷⁹ are as previously defined; 21) C _2-4 alkynyl X ¹⁸ C _1-4 alkyl R ⁷⁹ , wherein X ¹⁸ and R ⁷⁹ are as previously defined, and 22) C _1-4 alkyl R ¹⁰⁵ (C _1-4 alkyl) _x (X ¹⁸ ) _y R ¹⁰⁶ , where X ¹⁸ is as previously defined, x = 0 or 1, y = 0 or 1, and R ¹⁰⁵ and R ¹⁰⁶ each independently selected from hydrogen, C _1-3 alkyl, cyclopentyl, cyclohexyl and a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms independently selected from O, S and N, said C _1-3 alkyl the group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen and C _1-4 alkoxy, and said cyclic group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-4 cyanoalkyl, C _1-4 alky la, C _1-4 hydroxyalkyl, C _1-4 alkoxy, C _1-4 alkoksiS _1-4 alkyl, C _1-4 alkilsulfonilS _1-4 alkyl, C _1-4 alkoxycarbonyl, C _1-4 aminoalkyl, C _1-4 alkylamino, di (C _1-4 alkyl) amino, C _1-4 alkilaminoS _1-4 alkyl, di (C _1-4 alkyl) aminoC _1-4 alkyl, C _1-4 alkilaminoS _1-4 alkoxy, di (C _{1 -4} alkyl) amino C _1-4 alkoxy and the groups - (- O-) _f (C _1-4 alkyl) _g ring D, where f = 0 or 1, g = 0 or 1, ring D represents a 5-6 membered saturated a heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, said cyclic group may contain one or more substituents selected from C _1-4 alkyl, provided that R ¹⁰⁵ cannot represent hydrogen, and additionally, where any C _1-5 alkyl, C _2-5 alkenyl or C _2-5 alkynyl group in R ⁵⁶ X ¹⁰ may contain one or more substituents selected from hydroxy, halogen and amino, or its salts for the manufacture of a medicament used to achieve anti-angiogenic and / or vascular permeability-reducing effects in warm-blooded animals such as humans. 2. The use of the compounds of formula I according to claim 1

where ring C represents a 9-10 membered bicyclic moiety which may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may contain 1-3 heteroatoms independently selected from O, N and S; Z represents —O—, —NH—, —S—, —CH ₂ - or a single bond; R ¹ represents hydrogen, oxo, halogen, hydroxy, C _1-4 alkoxy, C _1-4 alkyl, C _1-4 alkoxymethyl, C _1-4 alkanoyl, C _1-4 haloalkyl, cyano, amino, C _2-5 alkenyl , C _2-5 alkynyl, C _1-3 alkanoyloxy, nitro, C _1-4 alkanoylamino, C _1-4 alkoxycarbonyl, C _1-4 alkylsulfanyl, C _1-4 alkylsulfinyl, C _1-4 alkylsulfonyl, carbamoyl, N-C _1-4 alkylcarbamoyl, N, N-di (C _1-4 alkyl) carbamoyl, aminosulfonyl, N-C _1-4 alkylaminosulfonyl, N, N-di (C _1-4 alkyl) aminosulfonyl, N- (C _1-4 alkylsulfonyl) amino, N- (C _1-4 alkylsulfonyl) -N- (C _1-4 alkyl) amino, N, N-di (C _1-4 alkylsulfonyl) amino or C _3-7 alkylene chain, bound u with two ring C atoms, n is 0 to 5; m is 0 to 3; R ² represents hydrogen, hydroxy, halogen, cyano, nitro, trifluoromethyl, C _1-3 alkyl, C _1-3 alkoxy, C _1-3 alkylsulfanyl, -NR ³ R ⁴ , where R ³ and R ⁴ , which may be the same or different, each represents hydrogen or C _1-3 alkyl, or R ⁵ X ¹ , where X ¹ represents a single bond, —O—, —CH ₂ -, —OC (O) -, —C (O) -, - S-, -SO-, -SO ₂ -, -NR ⁶ C (O), -C (O) NR ⁷ , -SO ₂ NR ⁸ -, -NR ⁹ SO ₂ - or -NR ¹⁰ -, where R ⁶ , R ⁷ , R ⁸ , R ⁹ and R ¹⁰ each independently represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ⁵ selected from one of the following twenty one groups: 1) hydrogen or C _1-5 alkyl, which may be unsubstituted or which may be substituted by one or more groups selected from hydroxy, fluorine and amino; 2) C _1-5 alkyl X ² C (O) R ¹¹ , where X ² is —O— or —NR ¹² -, where R ¹² is hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl) R ¹¹ is C _1-3 alkyl, —NR ¹³ R ¹⁴ or —OR ¹⁵ , where R ¹³ , R ¹⁴ and R ¹⁵ , which may be the same or different, each represents hydrogen, C _1-5 alkyl or C _{1- 3} alkoxyC _2-3 alkyl; 3) C _1-5 alkylX ³ R ¹⁶ , where X ³ is —O—, —S—, —SO—, —SO ₂ -, —OC (O) -, —NR ¹⁷ C (O) -, —C (O) NR ¹⁸ -, -SO ₂ NR ¹⁹ -, NR ²⁰ SO ₂ - or -NR ²¹ -, where R ¹⁷ , R ¹⁸ , R ¹⁹ , R ²⁰ and R ²¹ each independently represent hydrogen, C _{1- 3} alkyl or C _1-3 alkoxyC _2-3 alkyl, R ¹⁶ represents hydrogen, C _1-3 alkyl, cyclopentyl, cyclohexyl or a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms independently selected from O, S and N, said C _1-3 alkyl group may contain 1 or 2 substituents selected from oxo, hydroxy, halogeno and C _1-4 alkoxy, and said cyclic group may contain 1 or 2 substituents The selected from oxo, hydroxy, halogen, cyano, C _1-4 alkyl, C _1-4 hydroxyalkyl and C _1-4 alkoxy; 4) C _1-5 alkylX ⁴ C _1-5 alkylX ⁵ R ²² , where X ⁴ and X ⁵ , which may be the same or different, are each —O—, —S—, —SO—, —SO ₂ -, -NR ²³ C (O) -, -C (O) NR ²⁴ -, -SO ₂ NR ²⁵ -, -NR ²⁶ SO ₂ -or -NR ²⁷ -, where R ²³ , R ²⁴ , R ²⁵ , R ²⁶ and R ²⁷ each independently represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ²² represents hydrogen or C _1-3 alkyl; 5) R ²⁸ , where R ²⁸ represents a 5-6 membered saturated heterocyclic group (bonded via carbon or nitrogen) with 1-2 heteroatoms selected independently from O, S and N, said heterocyclic group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-4 cyanoalkyl, C _1-4 alkyl, C _1-4 hydroxyalkyl, C _1-4 alkoxy, C _1-4 alkoxyC _1-4 alkyl, C _1-4 alkylsulfonyl C _{1- 4} alkyl; 6) C _1-5 alkyl R ²⁸ , where R ²⁸ is as defined herein; 7) C _2-5 alkenyl R ²⁸ , where R ²⁸ is as defined; 8) C _2-5 alkynyl R ²⁸ , where R ²⁸ is as defined herein; 9) R ²⁹ , where R ²⁹ represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, S and N, said pyridonic, phenyl or an aromatic heterocyclic group may contain up to 5 substituents on an available carbon atom selected from hydroxy, halogen, amino, C _1-4 alkyl, C _1-4 alkoxy, C _1-4 hydroxyalkyl, C _1-4 aminoalkyl, C _1-4 alkylamino C _1-4 hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -C (O) NR ³⁰ R ^31, -NR ³² C (O) R ³³ - wherein R ^30, R ^31, R ³² and R ³³ to orye may be identical or different, each independently represents hydrogen, C _1-4 alkyl or C _1-3 alkoksiS _2-3 alkyl; 10) C _1-5 alkylR ²⁹ wherein R ²⁹ is as defined herein; 11) C _2-5 alkenyl R ²⁹ , where R ²⁹ is as defined herein; 12) C _2-5 alkynyl R ²⁹ , where R ²⁹ is as defined herein; 13) C _1-5 alkylX ⁶ R ²⁹ , where X ⁶ is —O—, —S—, —SO—, —SO ₂ -, —NR ³⁴ C (O) -, —C (O) NR ³⁵ -, -SO ₂ NR ³⁶ -, -NR ³⁷ SO ₂ - or -NR ³⁸ -, where R ³⁴ , R ³⁵ , R ³⁶ , R ³⁷ and R ³⁸ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ²⁹ is as defined herein; 14) C _2-5 alkenylX ⁷ R ²⁹ , where X ⁷ represents —O—, —S—, —SO—, —SO ₂ -, —NR ³⁹ C (O) -, —C (O) NR ⁴⁰ -, -SO ₂ NR ⁴¹ -, -NR ⁴² SO ₂ - or -NR ⁴³ -, where R ³⁹ , R ⁴⁰ , R ⁴¹ , R ⁴² and R ⁴³ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ²⁹ is as defined herein; 15) C _2-5 alkynyl X ⁸ R ²⁹ , where X ⁸ represents —O—, —S—, —SO—, —SO ₂ -, —NR ⁴⁴ C (O) -, —C (O) NR ⁴⁵ -, -SO ₂ NR ⁴⁶ -, -NR ⁴⁷ SO ₂ - or -NR ⁴⁸ -, where R ⁴⁴ , R ⁴⁵ , R ⁴⁶ , R ⁴⁷ and R ⁴⁸ each independently represents hydrogen, C _1-3 alkyl or C _{1- 3} alkoxyC _2-3 alkyl, R ²⁹ is as defined herein; 16) C _1-3 alkylX ⁹ C _1-3 alkylR ²⁹ , where X ⁹ represents —O—, —S—, —SO—, —SO ₂ -, —NR ⁴⁹ C (O) -, —C (O) NR ⁵⁰ -, -SO ₂ NR ⁵¹ -, -NR ⁵² SO ₂ - or -NR ⁵³ -, where R ⁴⁹ , R ⁵⁰ , R ⁵¹ , R ⁵² and R ⁵³ each independently represent hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ²⁹ is as defined herein; 17) C _1-3 alkylX ⁹ C _1-3 alkylR ²⁸ , where X ⁹ and R ²⁸ are as defined herein; 18) C _2-5 alkenyl, which may be unsubstituted or may be substituted by one or more groups selected from hydroxy, fluoro, amino, C _1-4 alkylamino, N, N-di (C _1-4 alkyl) amino, aminosulfonyl N-C _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 19) C _2-5 alkynyl, which may be unsubstituted or may be substituted by one or more groups selected from hydroxy, fluoro, amino, C _1-4 alkylamino, N, N-di (C _1-4 alkyl) amino, aminosulfonyl N-C _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 20) C _2-5 alkenyl X ⁹ C _1-4 alkyl R ²⁸ , where X ⁹ and R ²⁸ are as defined herein; and 21) C _2-5 alkynyl X ⁹ C _1-4 alkyl R ²⁸ , where X ⁹ and R ²⁸ are as defined herein; or its salts and prodrugs, for example, esters, amides or sulfides, to obtain a medicine used to achieve anti-angiogenic and / or vascular permeability-reducing effects in warm-blooded animals such as humans. 3. The use of the compounds of formula I according to claim 1, where R ² represents hydroxy, halogen, cyano, nitro, trifluoromethyl, C _1-3 alkyl, amino or R ⁵ X ¹ , where X ¹ as defined in claim 1, R ^{5 is} selected from one of the following twenty two groups: 1) C _1-4 alkyl, which may be unsubstituted or which may be substituted by one or more groups selected from fluorine, chlorine and bromine, or C _2-5 alkyl, which may be unsubstituted or substituted by one or more groups selected from hydroxy and amino; 2) C _2-3 alkylX ² C (O) R ¹¹ , where X ² is as defined in claim 1, and R ¹¹ is —NR ¹³ R ¹⁴ or —OR ¹⁵ , where R ¹³ , R ¹⁴ and R ¹⁵ , which may be the same or different, each represents C _1-4 alkyl or C _1-2 alkoxyethyl; 3) C _2-4 alkylX ³ R ¹⁶ , where X ³ is as defined in claim 1, and R ¹⁶ represents a group selected from C _1-3 alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl and tetrahydropyranyl, said C _1-3 alkyl group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen and C _1-2 alkoxy, and said cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl and tetrahydropyranyl may contain 1 or 2 s substituents selected from oxo, hydroxy, halogen, cyano, C _1-3 cyanoalkyl, C _1-3 alkyl, C _1-3 hydroxyalkyl, C _1-3 alkoxy, C _1-2 alkoxyC _1-3 alkyl, C _1-2 alkylsulfonylC _1-3 alkyl, C _1-3 alkoxycarbonyl, C _1-3 alkylamino, di (C _1-3 alkyl) amino, C _1-3 alkylamino C _1-3 alkyl, di (C _1-3 alkyl) aminoC _1-3 alkyl, C _1-3 alkilaminoS _1-3 alkoxy, di (C _1-3 alkyl) aminoC _1-3 alkoxy and a group - (- O-) _f (C _1-4 alkyl) _g koltsoD where f = 0 or 1 , g = 0 or 1, ring D represents a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomor Ohlin said cyclic group may contain one or more substituents selected from C _1-3 alkyl; 4) C _2-3 alkylX ⁴ C _2-3 alkylX ⁵ R ²² , where X ⁴ and X ⁵ are as defined in claim 1, R ²² represents hydrogen or C _1-3 alkyl; 5) R ²⁸ , where R ²⁸ is as defined in claim 1; 6) C _1-5 alkyl R ¹¹⁰ , where R ¹¹⁰ represents a group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidin-1-yl, azetidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl , 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, said group is bonded to C _1-5 alkyl via a carbon atom, and said group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-3 cyanoalkyl, C _1-3 alkyl, C _1-3 hydroxyalkyl, C _1-3 alkoxy, C _1-2 alkoxyC _1-3 alkyl, C _1-2 alkylsulfonylC _1-3 alkyl, C _{1 -3} alkoxycarbonyl, C _1-3 alkylamino, di (C _1-3 alkyl) amino, C _1-3 alkilaminoS _1-3 and lkila, di (C _1-3 alkyl) aminoC _1-3 alkyl, C _1-3 alkilaminoS _1-3 alkoxy, di (C _1-3 alkyl) aminoC _1-3 alkoxy and a group - (- O-) _f (C _1-3 alkyl) _g ring D, where f = 0 or 1, g = 0 or 1, ring D represents a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, said cyclic group may contain one or several substituents selected from C _1-3 alkyl, or C _2-4 alkyl R ¹¹¹ , where R ¹¹¹ represents a group selected from morpholino, thiomorpholino, azetidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl and piperidino, said group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-3 cyanoalkyl, C _1-3 alkyl, C _1-3 hydroxyalkyl, C _1-3 alkoxy, C _1-2 alkoxyC _1-3 alkyl, C _1-2 alkylsulfonyl C _1-3 alkyl, C _1-3 alkoxycarbonyl, C _1-3 alkylamino, di (C _1-3 alkyl) amino, C _1-3 alkylamino C _1-3 alkyl, di (C _1-3 alkyl) aminoC _1-3 alkyl, C _1-3 alkilaminoS _1-3 alkoxy, di (C _1-3 alkyl) aminoC _1-3 alkoxy and a group - (- O-) _f (C _1-3 alkyl) koltsoD _g where f = 0 or 1, g = 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinium a, imidazolidinyl, aeetidinila, morpholino and thiomorpholino, said cyclic group may contain one or more substituents selected from C _1-3 alkyl; 7) C _3-4 alkenyl R ¹¹² , where R ¹¹² represents R ¹¹⁰ or R ¹¹¹ , as defined herein; 8) C _3-4 alkynyl R ¹¹² , where R ¹¹² represents R ¹¹⁰ or R ¹¹¹ , as defined herein; 9) R ²⁹ , where R ²⁹ is as defined in claim 1; 10) C _1-4 alkyl R ²⁹ , where R ²⁹ is as defined in claim 1; 11) 1-R ²⁹ prop-1-en-3-yl or 1-R ²⁹ but-2-en-4-yl, where R ²⁹ is as defined in claim 1, provided that when R ⁵ is 1 —R ²⁹ prop-1-en-3-yl, R ²⁹ is linked to an alkenyl group through a carbon atom; 12) 1-R ²⁹ prop-1-yn-3-yl or 1-R ²⁹ but-2-yn-4-yl, where R ²⁹ is as defined in claim 1, provided that when R ⁵ is 1 —R ²⁹ prop-1-yn-3-yl, R ²⁹ is linked to an alkynyl group via a carbon atom; 13) C _1-5 alkylX ⁶ R ²⁹ , where X ⁶ and R ²⁹ are as defined in claim 1; 14) 1- (R ²⁹ X ⁷ ) but-2-en-4-yl, where X ⁷ and R ²⁹ are as previously defined; 15) 1- (R ²⁹ X ⁸ ) but-2-yn-4-yl, where X ⁸ and R ²⁹ are as defined in claim 1; 16) C _2-3 alkylX ⁹ C _1-3 alkylR ²⁹ , where X ⁹ and R ²⁹ are as defined in claim 1; 17) C _2-3 alkylX ⁹ C _1-3 alkylR ²⁸ , where X ⁹ and R ²⁸ are as defined in claim 1; 18) C _2-5 alkenyl, which may be unsubstituted or may be substituted by one or more fluorine atoms or one or two groups selected from hydroxy, fluorine, amino, C _1-4 alkylamino, N, N-di (C _{1- 4} alkyl) amino, aminosulfonyl, N — C _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 19) C _2-5 alkynyl, which may be unsubstituted or may be substituted by one or more fluorine atoms or one or two groups selected from hydroxy, fluorine, amino, C _1-4 alkylamino, N, N-di (C _{1- 4} alkyl) amino, aminosulfonyl, N — C _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 20) C _2-4 alkenyl X ⁹ C _1-3 alkyl R ²⁸ , where X ⁹ and R ²⁸ are as defined in claim 1; 21) C _2-4 alkynyl X ⁹ C _1-3 alkyl R ²⁸ where X ⁹ and R ²⁸ are as defined in claim 1; and 22) C _1-3 alkyl R ⁵⁴ (C _1-3 alkyl) _q (X ⁹ ) _r R ⁵⁵ , where X ⁹ , q, r, R ⁵⁴ and R ⁵⁵ are as defined in claim 1, and further, where any C _1-5 alkyl, C _2-5 alkenyl or C _2-5 alkynyl group in R ⁵ X ¹ may contain one or more substituents selected from hydroxy, halogen and amino. 4. The use of the compounds of formula I according to any one of the preceding paragraphs, where Z is —O—, —NH— or —S—. 5. The use of the compounds of formula I according to any one of the preceding paragraphs, where ring C represents a 9-10 membered heteroaromatic bicyclic fragment that contains 1-3 heteroatoms independently selected from O, N and S. 6. The use of the compounds of formula I according to any one of the preceding paragraphs, where R ¹ represents oxo, halogen, hydroxy, C _1-2 alkoxy, C _1-2 alkyl, C _1-2 alkoxymethyl, C _2-3 alkanoyl, C _1-2 haloalkyl, cyano, amino, C _2-4 alkenyl, C _2-4 alkynyl, C _2-3 alkanoyloxy, nitro, C _2-3 alkanoylamino, C _1-2 alkoxycarbonyl, C _1-2 alkylsulfanyl, C _1-2 alkylsulfinyl, C _1-2 alkylsulfonyl, carbamoyl, N-C _1-2 alkylcarbamoyl, N, N-di (C _1-2 alkyl) carbamoyl, aminosulfonyl, N-C _1-2 alkylaminosulfonyl, N, N-di (C _1-2 alkyl) aminosulfonyl, N- (C _1-2 alkylsulfonyl) amino, N- (C _1-2 alkylsulfonyl) -N- (C _1-2 alkyl) amine or C _3-7 alkylene chain bonded to two ring C atoms 7. The use of the compounds of formula I according to any one of the preceding paragraphs, where n = 0, 1 or 2. 8. The use of the compounds of formula I according to any one of the preceding paragraphs, where m = 1 or 2. 9. The compound of formula II

where the ring C, R ¹ , R ² and n are as defined in claim 1;  Zb is —O— or —S—; R ^2a represents hydrogen, halogen, C _1-3 alkyl, trifluoromethyl, C _1-3 alkoxy, C _1-3 alkylsulfanyl, -NR ^3a R ^4a , where R ^3a and R ^4a , which may be the same or different, each represents hydrogen or C _1-3 alkyl, or R ^5a (CH ₂ ) zaX ^1a , where R ^5a represents a 5- or 6-membered saturated heterocyclic group with 1-2 heteroatoms selected independently from O, S and N, wherein said heterocyclic group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-4 cyanoalkyl, C _1-4 alkyl, C _1-4 hydroxyalkyl, C _1-4 alkoxy, C _1-4 alkoxyC _1-4 alkyl , FROM _1-4 alkylsulfonylC _1-4 alkyl, C _1-4 alkoxycarbonyl, C _1-4 aminoalkyl, C _1-4 alkylamino, di (C _1-4 alkyl) amino, C _1-4 alkylamino C _1-4 alkyl, di (C _1-4 alkyl) aminoC _1-4 alkyl, C _1-4 alkilaminoS _1-4 alkoxy, di (C _1-4 alkyl) aminoC _1-4 alkoxy and a group - (- O-) _f (C _1-4 alkyl) _g ring D, where f = 0 or 1, g = 0 or 1, ring D represents a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms independently selected from O, S and N, said cyclic group may contain one or several substituents selected from C _1-4 alkyl, za represents an integer from 0 to 4, X ^1a represents t single bond, -O-, -CH ₂ -, -S-, -SO-, -SO ₂ -, -NR ^6a C (O) -, -C (O) NR ^7a -, -SO ₂ NR ^8a , —NR ^9a SO ₂ - or —NR ^10a -, where R ^6a , R ^7a , R ^8a , R ^9a and R ^10a each independently represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl; provided that R ^{2 is} not hydrogen and excluding compounds:  6,7-dimethoxy-4- (1-naphthylsulfanyl) quinazoline, 6,7-dimethoxy-4- (2-naphthylsulfanyl) quinazoline, 6,7-dimethoxy-4- (1-naphthyloxy) quinazoline and 6,7- dimethoxy-4- (2-naphthyloxy) quinazoline, and its salt. 10. The compound of formula II according to claim 9, where R ² is hydroxy, halogen, cyano, nitro, trifluoromethyl, C _1-3 alkyl, amino or R ⁵ X ¹ , where X ¹ is as defined in claim 1, R ⁵ are selected from one of the following twenty two groups: 1) C _1-4 alkyl, which may be unsubstituted or which may be substituted by one or more groups selected from fluorine, chlorine and bromine, or C _2-5 alkyl, which may be unsubstituted or substituted by one or more groups selected from hydroxy and amino; 2) C _2-3 alkylX ² C (O) R ¹¹ , where X ² is as defined in claim 1, R ¹¹ is —NR ¹³ R ¹⁴ or —OR ¹⁵ , where R ¹³ , R ¹⁴ and R ¹⁵ which may be the same or different, each represents C _1-4 alkyl or C _1-2 alkoxyethyl; 3) C _2-4 alkyl X ³ R ¹⁶ , where X ³ is as defined in claim 1, R ¹⁶ represents a group selected from C _1-3 alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, azetidinyl and tetrahydropyranyl, said C _1-3 alkyl group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen and C _1-2 alkoxy, and said cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl and tetrahydropyranyl contain 1 or 2 deputies stitelya selected from oxo, hydroxy, halogen, cyano, C _1-3 cyanoalkyl, C _1-3 alkyl, C _1-3 hydroxyalkyl, C _1-3 alkoxy, C _1-2 alkoksiS _1-3 alkyl, C _1-2 alkylsulfonylC _1-3 alkyl, C _1-3 alkoxycarbonyl, C _1-3 alkylamino, di (C _1-3 alkyl) amino, C _1-3 alkylamino C _1-3 alkyl, di (C _1-3 alkyl) aminoC _1-3 alkyl, C _1-3 alkilaminoS _1-3 alkoxy, di (C _1-3 alkyl) aminoC _1-3 alkoxy and a group - (- O-) _f (C _1-3 alkyl) _g ring D, wherein f = 0 or 1, g = 0 or 1, ring D represents a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpho ino, said cyclic group may contain one or more substituents selected from C _1-3 alkyl; 4) C _2-3 alkylX ⁴ C _2-3 alkylX ⁵ R ²² , where X ⁴ and X ⁵ are as defined in claim 1, R ²² represents hydrogen or C _1-3 alkyl; 5) R ²⁸ , where R ²⁸ is as defined in claim 1; 6) C _1-4 alkyl R ¹¹⁰ , where R ¹¹⁰ represents a group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidin-1-yl, azetidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl , 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, said group is bonded to C _1-4 alkyl via a carbon atom, and said group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-3 cyanoalkyl, C _1-3 alkyl, C _1-3 hydroxyalkyl, C _1-3 alkoxy, C _1-2 alkoxyC _1-3 alkyl, C _1-2 alkylsulfonylC _1-3 alkyl, C _{1 -3} alkoxycarbonyl, C _1-3 alkylamino, di (C _1-3 alkyl) amino, C _1-3 alkilaminoS _1-3 and lkila, di (C _1-3 alkyl) aminoC _1-3 alkyl, C _1-3 alkilaminoS _1-3 alkoxy, di (C _1-3 alkyl) aminoC _1-3 alkoxy and a group - (- O-) _f (C _1-3 alkyl) _g ring D, where f = 0 or 1, g = 0 or 1, ring D represents a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, said cyclic group may contain one or several substituents selected from C _1-3 alkyl)) or C _2-4 alkyl R ¹¹³ , where R ¹¹¹ represents a group selected from morpholino, thiomorpholino, azetidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl and piperidino, said group may contain 1 or 2 substituents selected from oxo, hydroxy, halogen, cyano, C _1-3 cyanoalkyl, C _1-3 alkyl, C _1-3 hydroxyalkyl, C _1-3 alkoxy, C _1-2 alkoxyC _1-3 alkyl, C _1-2 alkylsulfonylC _1-3 alkyl, C _1-3 alkoxycarbonyl, C _1-3 alkylamino, di (C _1-3 alkyl) amino, C _1-3 alkylamino C _1-3 alkyl, di ( C _1-3 alkyl) aminoC _1-3 alkyl, C _1-3 alkilaminoS _1-3 alkoxy, di (C _1-3 alkyl) aminoC _1-3 alkoxy and a group - (- O-) _f (C _1-4 alkyl ) _g ring D, where f = 0 or 1, g = 0 or 1, ring D represents a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperide nyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, said cyclic group may contain one or more substituents selected from C _1-3 alkyl; 7) C _3-4 alkenyl R ¹¹² , where R ¹¹² represents R ¹¹⁰ or R ¹¹¹ , as defined herein; 8) C _3-4 alkynyl R ¹¹² , where R ¹¹² represents R ¹¹⁰ or R ¹¹¹ , as defined herein; 9) R ²⁹ , where R ²⁹ is as defined in claim 1; 10) C _1-4 alkyl R ²⁹ , where R ²⁹ is as defined in claim 1; 11) 1-R ²⁹ prop-1-en-3-yl or 1-R ²⁹ but-2-en-4-yl, where R ²⁹ is as defined in claim 1, provided that when R ⁵ is 1 —R ²⁹ prop-1-en-3-yl, R ²⁹ is linked to an alkenyl group through a carbon atom; 12) 1-R ²⁹ prop-1-yn-3-yl or 1-R ²⁹ but-2-yn-4-yl, where R ²⁹ is as defined in claim 1, provided that when R ⁵ is 1 —R ²⁹ prop-1-yn-3-yl, R ²⁹ is linked to an alkynyl group via a carbon atom; 13) C _1-5 alkylX ⁶ R ²⁹ , where X ⁶ and R ²⁹ are as defined in claim 1; 14) 1- (R ²⁹ X ⁷ ) but-2-en-4-yl, where X ⁷ and R ²⁹ are as defined in claim 1; 15) 1- (R ²⁹ X ⁸ ) but-2-yn-4-yl, where X ⁸ and R ²⁹ are as defined in claim 1; 16) C _2-3 alkylX ⁹ C _1-3 alkylR ²⁹ , where X ⁹ and R ²⁹ are as defined in claim 1; 17) C _2-3 alkylX ⁹ C _1-3 alkylR ²⁸ , where X ⁹ and R ²⁸ are as defined in claim 1; 18) C _2-5 alkenyl, which may be unsubstituted or may be substituted by one or more fluorine atoms or one or two groups selected from hydroxy, fluorine, amino, C _1-4 alkylamino, N, N-di (C _{1- 4} alkyl) amino, aminosulfonyl, NC _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 19) C _2-5 alkynyl, which may be unsubstituted or may be substituted by one or more fluorine atoms or one or two groups selected from hydroxy, fluorine, amino, C _1-4 alkylamino, N, N-di (C _{1- 4} alkyl) amino, aminosulfonyl, NC _1-4 alkylaminosulfonyl and N, N-di (C _1-4 alkyl) aminosulfonyl; 20) C _2-4 alkenyl X ⁹ C _1-3 alkyl R ²⁸ , where X ⁹ and R ²⁸ are as defined in claim 1; 21) C _2-4 alkynyl X ⁹ C _1-3 alkyl R ²⁸ , where X ⁹ and R ²⁸ are as defined in claim 1, and 22) C _1-3 alkylR ⁵⁴ (C _1-3 alkyl) _q (X ⁹⁾ _{r R} ^55, wherein X ^9, q, r, R ⁵⁴ and R ⁵⁵ are as defined in claim 1, and further, where any C _1-5 alkyl, C _2-5 alkenyl or C _2-5 alkynyl group in R ⁵ X ¹ may contain one or more substituents selected from hydroxy, halogen and amino. 11. A compound according to any one of claims 9 and 10, wherein Zb is —O—. 12. The compound according to any one of claims 9, 10 and 11, where ring C represents a 9-10 membered heteroaromatic bicyclic fragment that contains 1-3 heteroatoms independently selected from O, N and S. 13. The compound according to any one of claims 9, 10, 11 and 12, where R ¹ represents oxo, halogen, hydroxy, C _1-2 alkoxy, C _1-2 alkyl, C _1-2 alkoxymethyl, C _2-3 alkanoyl , C _1-2 haloalkyl, cyano, amino, C _2-4 alkenyl, C _2-4 alkynyl, C _2-3 alkanoyloxy, nitro, C _2-3 alkanoylamino, C _1-2 alkoxycarbonyl, C _1-2 alkylsulfanyl, C _1-2 alkylsulfinyl, C _1-2 alkylsulfonyl, carbamoyl, NC _1-2 alkylcarbamoyl, N, N-di (C _1-3 alkyl) carbamoyl, aminosulfonyl, NC _1-2 alkylaminosulfonyl, N, N-di (C _{1- 2} alkyl) aminosulfonyl, N- (C _1-2 alkylsulfonyl) amino, N- (C _1-2 alkylsulfonyl) -N- (C _1-2 alkyl) amino or C _3-7 alkylene chain, bound u with two ring C. atoms 14. The compound according to any one of paragraphs. 9-13, where n = 0, 1 or 2. 15. The compound of formula IIb

where the ring C, R ¹ , R ² and n are as defined in claim 1;  Zb represents —O—; R ^2a is as defined in claim 9 provided that R ² does not take one of the following values: hydrogen, substituted or unsubstituted C _1-5 alkyl, halogen, C _1-5 alkoxy, C _2-5 alkenyl, phenoxy or phenylC _1-5 alkoxy, or its salt. 16. The compound according to claim 9, selected from: 6-methoxy-7 - ((1-methylpiperidin-4-yl) methoxy) -4- (2-naphthyloxy) quinazoline, 6-methoxy-7 - ((1-methylpiperidin-4-yl) methoxy) -4- (quinolin-7-yloxy) quinazoline, 7- (3- (1,1-dioxothiomorpholino) propoxy) -6-methoxy-4- (quinolin-7-yloxy) quinazoline, 6-methoxy-7- (3- (4-methylpiperazin-1-yl) propoxy) -4- (quinolin-7-yloxy) quinazoline, 6-methoxy-7 - ((1-methylpiperidin-3-yl) methoxy) -4- (quinolin-7-yloxy) quinazoline, 4- (4-chloroquinolin-7-yloxy) -6-methoxy-7- (3-morpholino-propoxy) quinazoline, 6-methoxy-7 - ((1-methylpiperidin-4-yl) methoxy) -4- (4-methylquinolin-7-yloxy) quinazoline, 6-methoxy-4- (4-methylquinolin-7-yloxy) -7- (3- (pyrrolidin-1-yl) propoxy) quinazoline, 6-methoxy-7- (2- (2-methoxyethoxy) ethoxy) -4- (quinolin-7-yloxy) quinazoline, 6-methoxy-7 - ((1- (2-methylsulfonylethyl) piperidin-4-yl) methoxy) -4- (quinolin-7-yloxy) quinazoline, 4- (2,3-dimethylindol-5-yloxy) -6-methoxy-7- (1-methylpiperidin-4-ylmethoxy) quinazoline, 4- (2,3-dimethylindol-5-yloxy) -6-methoxy-7- (3-pyrrolidin-1-ylpropoxy) quinazoline, 6-methoxy-7- (1-methylpiperidin-4-ylmethoxy) -4- (2-trifluoromethylindol-5-yloxy) quinazoline, 6-methoxy-7- (3-pyrrolidin-1-ylpropoxy) -4- (2-trifluoromethylindol-5-yloxy) quinazoline, (R, S) -4- (3-fluoroquinolin-7-yloxy) -6-methoxy-7 - ((1-methylpiperidin-3-yl) methoxy) quinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (3-methylsulfonylpropoxy) quinazoline, 7- (3-N, N-dimethylaminopropoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2- (2-morpholino-ethoxy) ethoxy) quinazoline, 7- (2- (N, N-diethylamino) ethoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-7- (3-piperidinopropoxy) -4- (quinolin-7-yloxy) quinazoline, 4- (2-methylindol-5-yloxy) -7- (3-morpholinopropoxy) quinazoline, 4- (2-methylindol-5-yloxy) -7- (2- (piperidin-1-yl) ethoxy) -quinazoline, 4- (2-methylindol-5-yloxy) -7- (2- (1H-1,2,4-triazol-1-yl) ethoxy) quinazoline, 6-methoxy-7- (3-piperidinopropoxy) -4- (6-trifluoromethylindol-5-yloxy) quinazoline, 7- (3- (methylsulfonyl) propoxy) -4- (2-methylindol-5-yloxy) quinazoline, 7- (3- (N, N-dimethylamino) propoxy) -4- (2,3-dimethylindol-5-yloxy) -6-methoxyquinazoline, 4- (2,3-dimethylindol-5-yloxy) -6-methoxy-7- (1-methylpiperidin-3-ylmethoxy) quinazoline, 7- (2- (N, N-diethylamino) ethoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (2- (piperidin-2-yl) ethoxy) -quinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (2- (piperidin-1-yl) ethoxy) -quinazoline, 4- (indol-6-yloxy) -6-methoxy-7- (3-morpholinopropoxy) quinazoline, 7- (3- (ethylsulfonyl) propoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-4- (3-methylindol-5-yloxy) -7- (3-piperidino-propoxy) quinazoline, 7- (2-hydroxy-3-piperidinopropoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 7- (2-hydroxy-3- (4-methylpiperazin-1-yl) propoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2- (N-methylamino) ethoxy) quinazoline and 7- (2-hydroxy-3- (isopropylamino) propoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, or its salt. 17. The compound according to claim 9, selected from 6-methoxy-7- (3-morpholinopropoxy) -4- (quinolin-7-yloxy) -quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7 - ((1-methylpiperidin-4-yl) methoxy) quinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (1-methylpiperidin-4-ylmethoxy) quinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (3-pyrrolidin-1-ylpropoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (3-methylsulfonyl-propoxy) quinazoline, 7 - ((1-cyanomethyl) piperidin-4-ylmethoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2-morpholinoethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2-pyrrolidin-1-ylethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (1-methylpiperidin-3-ylmethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2-piperidinoethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2- (N-methyl-N- (4-pyridyl) amino) ethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (3-morpholino-propoxy) quinazoline, 6-methoxy-7- (2- (2-methoxyethoxy) ethoxy) -4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2- (1H-1,2,4-triazol-1-yl) ethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2- (2- (4-methylpiperazin-1-yl) ethoxy) ethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (3-piperidino-propoxy) quinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (3-piperidinopropoxy) quinazoline, 6-methoxy-7- (1- (2-methoxyethyl) piperidin-4-ylmethoxy) -4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7 - ((2- (2-pyrrolidin-1-yl-ethyl) carbamoyl) vinyl) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (3- (4-methylpiperazin-1-yl) propoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (piperidin-4-ylmethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2- (piperidin-4-yloxy) ethoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2- (N-methyl-N-methylsulfonylamino) ethoxy) quinazoline, 7- (2- (1- (2-cyanoethyl) piperidin-4-yloxy) ethoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 4- (2-methylindol-5-yloxy) -7- (3- (pyrrolidinyl) propoxy) -quinazoline, 4- (2-methylindol-5-yloxy) -7- (3- (1,1-dioxothiomorpholino) propoxy) quinazoline, 4- (2-methylindol-5-yloxy) -7- (piperidin-4-ylmethoxy) -quinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (2- (2-methoxyethoxy) ethoxy) quinazoline, 7- (3- (N, N-dimethylamino) propoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, 7- (3- (N, N-diethylamino) propoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, 7- (3- (1,1-dioxothiomorpholino) propoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (2- (4-pyridyloxy) ethoxy) quinazoline, 4- (indol-6-yloxy) -6-methoxy-7- (3-piperidinopropoxy) quinazoline, 7- (1- (2-methoxyethyl) piperidin-4-ylmethoxy) -4- (2-methylindol-5-yloxy) quinazoline, 7- (2-hydroxy-3-morpholinopropoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 7- (2- (1- (2-methoxyethyl) piperidin-4-yl) ethoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 7- (2-hydroxy-3-pyrrolidin-1-ylpropoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 7- (3- (N, N-diethylamino) -2-hydroxypropoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 7- (3- (1,1-dioxothiomorpholino) propoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (2- (4-pyridyloxy) ethoxy) quinazoline, 4- (indol-5-yloxy) -6-methoxy-7- (3-morpholinopropoxy) quinazoline, (2R) -6-methoxy- (2-methyl-1H-indol-5-yloxy) -7- (2-hydroxy-3-piperidinopropoxy) quinazoline, (5R) -6-methoxy-4- (2-methyl-1H-indol-5-yloxy) -7- (2-oxopyrrolidin-5-ylmethoxy) quinazoline, 4- (4-bromindol-5-yloxy) -6-methoxy-7- (3-piperidino-propoxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (1- (2- (pyrrolidin-1-yl) ethyl) -piperidin-4-ylmethoxy) quinazoline, (2R) -7- (2-hydroxy-3- (pyrrolidin-1-yl) propoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, (2R) -7- (2-hydroxy-3-morpholinopropoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, (2R) -7- (2-hydroxy-3-piperidinopropoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, (2R) -7- (2-hydroxy-3 - ((N, N-diisopropyl) amino) propoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, (2R) -7- (2-hydroxy-3-piperidinopropoxy) -4- (indol-5-yloxy) -6-methoxyquinazoline, (2R) -7- (2-hydroxy-3-piperidinopropoxy) -6-methoxy-4- (3-methylindol-5-yloxy) quinazoline, (2R) -7- (2-hydroxy-3- (pyrrolidin-1-yl) propoxy) -6-methoxy-4- (3-methylindol-5-yloxy) quinazoline, (2R) -7- (2-hydroxy-3- (pyrrolidin-1-yl) propoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, (2R) -7- (2-hydroxy-3- (4-methylpiperazin-1-yl) propoxy) -6-methoxy-4- (2-methylindol-5-yloxy) quinazoline, 6-methoxy-4- (2-methylindol-5-yloxy) -7- (1- (2-morpholinoethyl) piperidin-4-ylmethoxy) quinazoline, 4- (3-fluoro-quinolin-7-yloxy) -6-methoxy-7- (3-piperidino-propoxy) quinazoline, 4- (3-fluoro-quinolin-7-yloxy) -6-methoxy-7- (3- (pyrrolidin-1-yl) propoxy) quinazoline, 6-methoxy-7- (3- (pyrrolidin-1-yl) propoxy) -4- (1H-pyrrolo [2,3-6] pyridin-5-yloxy) quinazoline, (2S) -6-methoxy- (2-methyl-1H-indol-5-yloxy) -7- (2-hydroxy-3-piperidinopropoxy) quinazoline, and 4- (6-fluoro-2-methylindol-5-yloxy) -6-methoxy-7- (3- (pyrrolidin-1-yl) propoxy) quinazoline or its salt. 18. The compound according to claim 9, selected from 6-methoxy-4- (2-methylindol-5-yloxy) -7- (3- (pyrrolidin-1-yl) propoxy) quinazoline, 4- (4-fluorindol-5-yloxy) -6-methoxy-7- (1-methylpiperidin-4-ylmethoxy) quinazoline, 4- (4-fluorindol-5-yloxy) -6-methoxy-7- (3- (4-methylpiperazin-1-yl) propoxy) quinazoline, 4- (6-fluorindol-5-yloxy) -6-methoxy-7- (3- (pyrrolidin-1-yl) propoxy) quinazoline, 4- (4-fluorindol-5-yloxy) -6-methoxy-7- (3- (pyrrolidin-1-yl) propoxy) quinazoline, 4- (4-fluorindol-5-yloxy) -6-methoxy-7- (3-piperidino-propoxy) quinazoline, 4- (4-fluoro-2-methylindol-5-yloxy) -6-methoxy-7- (3- (pyrrolidin-1-yl) propoxy) quinazoline, 4- (4-fluoro-2-methylindol-5-yloxy) -6-methoxy-7- (3-piperidinopropoxy) quinazoline, 4- (4-fluoro-2-methylindol-5-yloxy) -6-methoxy-7 - ((1-methylpiperidin-4-yl) methoxy) quinazoline, 4- (4-fluoro-2-methylindol-5-yloxy) -6-methoxy-7- (3- (4-methylpiperazin-1-yl) propoxy) quinazolm, 4- (4-fluorindol-5-yloxy) -6-methoxy-7- (2- (1-methylpiperidin-4-yl) ethoxy) quinazoline, (2R) -7- (2-hydroxy-3- (pyrrolidin-1-yl) propoxy) -4- (4-fluoro-2-methylindol-5-yloxy) -6-methoxyquinazoline and 4- (4-fluoro- 2-methylindol-5-yloxy) -6-methoxy-7- (2- (1-methylpiperidin-4-yl) ethoxy) quinazoline, or its salt. 19. The compound according to claim 9 in the form of a pharmaceutically acceptable salt. 20. A method of obtaining a compound of formula I or its salt, comprising: (a) the interaction of the compounds of formula III

where R ² and m are as defined in claim 1; L ¹ represents a substituted fragment with a compound of formula IV

where the ring C, R, Z and n are as defined in claim 1., (b) a compound of formula I or a salt thereof, wherein at least one R ² is R ⁵ X ¹ , where R ⁵ is as defined in claim 1, and X ¹ is —O—, —S—, —OOC (O) - or —NR ¹⁰ -, where R ¹⁰ independently represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, can be obtained by reacting a compound of formula V

where the ring C, Z, R ¹ , R ² and n are as defined in claim 1; X ¹ is as previously defined in this section;  s = 0 - 2 with a compound of formula VI

where R ^{5 is} defined according to claim 1, a L ¹ is as defined in this description, (c) a compound of formula I or a salt thereof, wherein at least one R ² is R ⁵ X ¹ , where R ⁵ is as previously defined, X ¹ is —O—, —S—, —OC (O ) - or -NR ¹⁰ -, where R ¹⁰ represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, can be obtained by reacting a compound of formula VII

with the compound of formula VIII

where L ¹ , R ¹ , R ² , R ⁵ , ring C, Z and n are as defined in claim 1, and L ¹ , s and X ¹ are as defined in this description; (d) a compound of formula I or a salt thereof, wherein at least one R ² is R ⁵ X ¹ , where X ¹ is as defined in claim 1, and R ⁵ is —C _1-5 alkyl R ¹¹³ , where R ^{113 is} selected from one of the following nine groups: 1) X ¹⁹ C _1-3 alkyl, where X ¹⁹ represents —O—, —S—, —SO ₂ , —NR ¹¹⁴ C (O) or —NR ¹¹⁵ SO ₂ -, where R ¹¹⁴ and R ¹¹⁵ , which may be the same or different, represent hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl; 2) NR ¹¹⁶ R ¹¹⁷ , where R ¹¹⁶ and R ¹¹⁷ , which may be the same or different, are hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl; 3) X ²⁰ C _1-5 alkylX ⁵ R ²² , where X ²⁰ represents —O—, —S—, —SO ₂ , —NR ¹¹⁸ C (O), —NR ¹¹⁹ SO ₂ - or —NR ¹²⁰ -, where R ¹¹⁸ , R ¹¹⁹ and R ¹²⁰ , which may be the same or different, each represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, X ⁵ and R ²² are as defined in claim 1 ; 4) R ²⁸ , where R ²⁸ is as defined in claim 1; 5) X ²¹ R ²⁹ , where X ²¹ represents —O—, —S—, —SO ₂ , —NR ¹²¹ C (O), —NR ¹²² SO ₂ -, or —NR ¹²³ -, where R ¹²¹ , R ^122, and R ¹²³ , which may be the same or different, each represents hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ²⁹ is as previously defined; 6) X ²² C _1-3 alkyl R ²⁹ , where X ²² represents —O—, —S—, —SO ₂ -, —NR ¹²⁴ C (O), —NR ¹²⁵ SO ₂ - or —NR ¹²⁶ -, where R ¹²⁴ , R ¹²⁵ and R ¹²⁶ each independently represent hydrogen, C _1-3 alkyl or C _1-3 alkoxyC _2-3 alkyl, R ²⁹ is as defined in claim 1; 7) R ²⁹ , where R ²⁹ is as defined in claim 1; 8) X ²² C _1-4 alkyl R ²⁸ where X ²² and R ²⁸ are as defined in claim 1, and 9) R ⁵⁴ (C _1-4 alkyl) _q (X ⁹ ) _r R ⁵⁵ , where q, r, X ⁹ , R ⁵⁴ and R ⁵⁵ are as defined in claim 1, can be obtained by reacting a compound of formula IX

where X ¹ , R ¹ , R ² , ring C, Z and n are as defined in claim 1; L ¹ and s are as defined herein, with a compound of formula X

where R ¹¹³ is as defined herein; (e) a compound of formula I and or its salt, where one or more substituents (R ² ) _m is —NR ¹²⁷ R ¹²⁸ , where one (and the other is hydrogen), or both R ¹²⁷ and R ¹²⁸ are C _1-3 alkyl can be obtained by reacting compounds of formula I, where the substituent (R ² ) _m represents an amino group and an alkylating agent; (f) a compound of formula I and a salt thereof, wherein X ¹ is —SO— or —SO ₂ - can be prepared by oxidizing the corresponding compound in which X ¹ is —S — or —SO— and when a salt of a compound of formula I of obtaining the target salt is used by the interaction of the obtained compound with an acid or base. 21. A pharmaceutical composition comprising, as an active ingredient, a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 9 in combination with a pharmaceutically acceptable excipient or carrier. 22. A method of obtaining an anti-angiogenic and / or vascular permeability-reducing action in warm-blooded animals in need of such treatment, comprising administering to said animal an effective amount of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof. 23. The compound 4-fluoro-5-hydroxy-2-methylindole or its salt. 24. The compound 4-fluoro-5-hydroxyindole or its salt. 25. The compound 6-fluoro-5-hydroxy-2-methylindole or its salt. 26. The compound 6-fluoro-5-hydroxyindole or its salt. 27. A method for producing 4-fluoro-5-hydroxy-2-methylindole according to any of the methods described in example 237. 28. A method for producing 4-fluoro-5-hydroxyindole as described in Example 242. 29. The method of obtaining 6-fluoro-5-hydroxyindole, as described in example 242. 30. The method of obtaining 6-fluoro-5-hydroxy-2-methylindole, as described in example 250.